Zoster Treatment Market Share

North America Market Insights

North America is the dominant region in the zoster treatment market and is poised to hold share of 38.7% with a CAGR of 6.8% by 2037. The market is fueled by the strong public insurance systems, fast adoption of antiviral and vaccine therapies, and early diagnosis. The U.S. market is also expanding due to a rise in Medicare Part D reimbursement and vaccination campaigns through the CDC and innovation by key players in pharmaceutical companies, supported by AHRQ and NIH funding. Canada’s market is driven by the federal vaccination programs and funding across Ontario and British Columbia. Both countries have strong benefits in healthcare awareness, inclusion of zoster antivirals, and digital prescription systems.

The zoster treatment market in the U.S. is driven by federal policies that focus on early treatment, increased insurance coverage, and the incorporation of antiviral treatments into geriatric care streams. The CDC initiated increased vaccination campaigns during 2023, enhancing public awareness and vaccine uptake among adults over 50 years. At the same time, Medicare Part D reforms have expanded access to zoster antivirals, and spending went up to USD 800.4 million in 2024, which is a 15.8% hike over 2020. As per AHRQ, early antiviral treatment of postherpetic neuralgia decreased hospitalization expenditures by 26.9%, upholding the wisdom of reimbursement consonance. As the elderly population keeps expanding, the need for cost-effective, scalable zoster care will continue to be one of the most important priorities for U.S. healthcare policy.

Asia Pacific Market Insights

The APAC region is the fastest-growing sector in the zoster treatment market and is projected to hold the market share of 22.7% with a CAGR of 7.1% in 2037. The market is fueled by the rising elderly population, an increase in government investment in antivirals and preventive therapies, and expanding healthcare infrastructure. Further, India, China, Japan, South Korea, and Malaysia are experiencing a rise in herpes zoster disease, mainly among patients aged above 50. India and Malaysia are adopting cost cost-sensitive model to increase the budget allocation and manage the growing patient cases. The region has an increased awareness of the disease and improved diagnostic capabilities to address the market demand.

China holds the maximum share in the zoster treatment market and is expected to hold the market share of 9.5% in the APAC region in 2037. China has emerged as one of the largest markets for zoster treatments. Total government expenditure on zoster-related treatment grew 15.4% in five years, spurred by increasing incidence among the elderly population aged above 60 and the addition of priority antivirals to the National Reimbursement Drug List. More than 1.8 million patients were diagnosed with shingles in 2023, and key pharmaceutical coverage was rolled out to lower-tier cities via hospital groups linked to the government.

Europe Market Insights

The zoster treatment market in Europe is anticipated to account for 28.3% of market revenue, with a CAGR of 6.1% by 2037. The market in Europe is driven by the strong healthcare infrastructure, extensive vaccine and antiviral therapy reimbursement via national insurance programs, and an aging population. Zoster therapy is becoming more popular in Europe as people become more aware of postherpetic neuralgia (PHN), preventative immunization programs are extended, and antiviral medications are being integrated into elder care through policy. An estimation of 126.5 million people in Europe will be aged above 60 in 2037, presenting a high-value opportunity for manufacturers to make vaccines and antiviral solutions for the treatment.

Germany is leading the zoster treatment market in Europe and is expected to have a market share of 7.9% in 2037. Germany is the largest shareholder in the zoster treatment market, and expenditure reached €4.4 billion in 2024, as estimated by the Federal Ministry of Health (BMG). Both zoster vaccines and antiviral treatments are covered by the statutory health insurance system of the country (GKV), thus making them universally accessible to people above 60 years. As reported by the German Medical Association, public hospital networks dispensed more than 1.8 million prescriptions for zoster in 2023. Continuous investment in geriatric medicine and post-acute care also fuels uptake.

Government Policy Table in Europe (2021–2025)